(Q48368367)

11 February 2018

title

Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. (English)

1 reference

11 February 2018

0 references

1 reference

17

1 reference

11 February 2018

Silvana Guerriero

Silvana Guerriero

8

0 references

Claudia Fabiani

Claudia Fabiani

1

0 references

Giacomo Emmi

Giacomo Emmi

4

0 references

Mauro Galeazzi

14

Mauro Galeazzi

1 reference

11 February 2018

12

Fiorella Fusco

1 reference

11 February 2018

Jurgen Sota

2

Jurgen Sota

1 reference

11 February 2018

Bruno Frediani

13

Bruno Frediani

1 reference

11 February 2018

Gian Marco Tosi

16

Gian Marco Tosi

1 reference

11 February 2018

Giuseppe Lopalco

7

Giuseppe Lopalco

1 reference

11 February 2018

Lorenzo Vannozzi

5

Lorenzo Vannozzi

1 reference

11 February 2018

Daniela Bacherini

6

Daniela Bacherini

1 reference

11 February 2018

Florenzo Iannone

15

Florenzo Iannone

1 reference

11 February 2018

Vincenzo Venerito

9

Vincenzo Venerito

1 reference

11 February 2018

author name string

Antonio Vitale

3

1 reference

11 February 2018

Ida Orlando

10

1 reference

11 February 2018

Rossella Franceschini

11

1 reference

11 February 2018

publication date

3 November 2017

1 reference

11 February 2018

Ocular Immunology and Inflammation

published in

1 reference

11 February 2018

page(s)

1-6

1 reference

11 February 2018

Behçet's syndrome pathophysiology and potential therapeutic targets

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Ocular Involvement in Systemic Autoimmune Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Ocular features of Behcet's disease: an international collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Quality of life impairment in Behçet's disease and relationship with disease activity: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

EULAR recommendations for the management of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Validation of the revised International Criteria for Behcet's Disease (ICBD) in Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Genetic and non-genetic factors affecting the visual outcome of ocular Behcet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Uveitis in Behçet disease: an analysis of 880 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1391297

10.1080/09273948.2017.1391297

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

PubMed ID

29099660

1 reference

11 February 2018